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Abstract
A metabolome-wide genome-wide association study (mGWAS) aims to discover the effects
of genetic variants on metabolome phenotypes. Most mGWASes use as phenotypes con-
centrations of limited sets of metabolites that can be identified and quantified from spectral
information. In contrast, in an untargeted mGWAS both identification and quantification are
forgone and, instead, all measured metabolome features are tested for association with
genetic variants. While the untargeted approach does not discard data that may have
eluded identification, the interpretation of associated features remains a challenge. To
address this issue, we developed metabomatching to identify the metabolites underlying
significant associations observed in untargeted mGWASes on proton NMR metabolome
data. Metabomatching capitalizes on genetic spiking, the concept that because metabolome
features associated with a genetic variant tend to correspond to the peaks of the NMR spec-
trum of the underlying metabolite, genetic association can allow for identification. Applied to
the untargeted mGWASes in the SHIP and CoLaus cohorts and using 180 reference NMR
spectra of the urine metabolome database, metabomatching successfully identified the
underlying metabolite in 14 of 19, and 8 of 9 associations, respectively. The accuracy and
efficiency of our method make it a strong contender for facilitating or complementing meta-
bolomics analyses in large cohorts, where the availability of genetic, or other data, enables
our approach, but targeted quantification is limited.
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Author summary
Metabolome-wide genome-wide association studies aim to discover how genetic variation
affects metabolome traits. Such studies typically follow an acquire-identify-associate pro-
cedure: metabolome data are acquired experimentally, metabolites are identified in the
experimental data and their concentrations quantified, and the metabolite concentrations
are tested for association with genetic variants. The untargeted approach follows instead
an acquire-associate-identify procedure: the experimental data are binned into metabo-
lome features, and the features tested directly for genetic association. When the metabo-
lome is measured by proton NMR spectroscopy, genetically associated features tend to
correspond to peaks in the NMR spectrum of the underlying metabolites. This inherent
property of the untargeted approach acts as a genetic spiking which informs on the identi-
ties of involved metabolites. Metabomatching is a method that uses genetic spiking infor-
mation to identify the metabolite candidates, listed in a spectral database, most likely to
underlie observed feature associations. Here, we present the method and its software, and
evaluate its performance.
Introduction
Since the seminal metabolome-wide genome-wide association study (mGWAS) by Gieger
et al. in 2008 [1], mGWASes performed on blood and urine spectral metabolome phenotypes
have uncovered an increasing part of the heritable variability of the human metabolome
through the discovery of hundreds of genetically influenced metabolome phenotypes [2–4].
Most mGWASes use estimated metabolite concentrations as phenotypes [1, 5–10]. In such
targeted mGWASes, metabolite concentrations are obtained by quantification [11] of spectral
metabolome data produced by mass spectrometry (MS) or nuclear magnetic resonance
(NMR) spectroscopy. While targeted approaches pave the way for reproducible metabolomics,
only a fraction of the measured metabolome data is quantified into metabolite concentrations
due to the arduous nature of metabolite identification [12–16]. In Rueedi et al. [17], we used
an untargeted approach [18–20]: we binned then normalized the NMR data, and tested the
resulting bin intensities, which we called metabolome features, for association with genotypes.
We then sought metabolite identification only for significantly associated metabolome
features. To do so, we employed an inherent characteristic of the untargeted approach:
genetic spiking. If the genetic component of a metabolite concentration is detected in the
untargeted mGWAS, then the relevant genotype will associate with metabolome features
that correspond to the peaks of the NMR spectrum of the metabolite. Much as metabolite
spiking does by flooding a sample with a metabolite of interest, genetic spiking isolates, by
genetic association, the spectrum of the genetically influenced metabolite. However, whereas
the aim of metabolite spiking is to determine an unknown spectrum for a known metabolite,
we developed metabomatching to use genetic spiking to identify an unknown metabolite
from a known spectrum.
We previously showed that metabolite identification using the metabomatching procedure
works in principle [17, 20], and applied it to identify the metabolite involved in a novel SNP-
feature association. Here, we further develop metabomatching, present its core concepts and
data, perform numerical simulations, and evaluate its performance on two sets of mGWAS
data. We also present the metabomatching software, describe its implementation and settings,
and highlight the best practices and pitfalls of its application.
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Materials and methods
Metabolome features are obtained by reducing the experimental NMR spectra into bins
along the chemical shift range. This binning can be uniform or adaptive [13, 21–23], and is
applied during standard processing of the NMR data, among other steps such as alignment or
normalization. In an untargeted mGWAS, the quantification into metabolite concentrations is
skipped, and the metabolome features are tested directly for association with genetic variants,
such as single nucleotide polymorphisms (SNPs).
Any observed SNP-feature association, however, is but a proxy for the genetic effect of the
SNP on the concentration of a certain metabolite. Metabolome features are derived from the
NMR spectra of the measured samples, which in turn are combinations of the NMR spectra of
the metabolites contained in the samples. Therefore, the genetic effect of a SNP on the concen-
tration of a metabolite can be detected by the associations between the SNP and the metabo-
lome features that match peaks in the NMR spectrum of the metabolite. This match between
associated features and peaks of the spectrum allows, in principle, to identify the underlying
metabolite.
To formalize the notion of genetic spiking, we call the collection of association p-values,
effect sizes (β), and standard errors (s) resulting from the simple linear regressions between a
SNP and all metabolome features the pseudospectrum of the SNP. As shown in Fig 1A for
rs37369 in AGXT2, the pseudospectrum (−log) p-values mirror the NMR spectrum of the
underlying metabolite 3-aminoisobutyrate almost exactly.
Metabomatching uses genetic spiking towards the identification of underlying metabolites:
for a SNP that associates significantly with at least one metabolome feature, metabomatching
compares the pseudospectrum of the SNP to the NMR spectrum of each metabolite listed in a
Fig 1. AGXT2 pseudospectrum and 3-aminoisobutyrate NMR spectrum, descriptions, and metabomatching match sets. (A) The upper plot shows
the experimental NMR spectrum of 3-aminoisobutyrate. The lower plot shows the (-log) p-values of the pseudospectrum of rs37369 in AGXT2, when
p < 10−3. There is a close match between the experimental spectrum and the pseudospectrum, as the four sets of features that associate (p < 5 × 10−8) with
rs37369 correspond to the principal peaks of the spectrum. (B) Taking a more detailed view of the spectrum descriptions (from HMDB), we see that the
peaks of 3-aminoisobutyrate group into six clusters (labeled A through F). The multiplet ranges for clusters A, C, and E enclose their corresponding peaks
well, padding by an average of 0.023 ppm. The multiplet range for cluster F is significantly wider, padding by 0.062 ppm. Approximating cluster areas as the
product of the width of the cluster with the average height of the peaks in the cluster, then scaling, we find area-derived proton counts of 2.8, 0.7, 1.1, 1.2 for
clusters A, C, E, and F, respectively. These counts are coherent with the listed proton counts of 3, 1, 1, and 1 for the respective multiplet ranges. Applying this
same approximation for clusters B and D results in area-derived proton counts of 0.0, and 0.2. Because this implies corresponding multiplet proton counts of
0, we may consider the two spectrum descriptions essentially coherent, even though no multiplet ranges are listed for clusters B and D. (C) Match sets
obtained from the peak and multiplet descriptions of the 3-aminoisobutyrate spectrum, for features resulting from a uniform NMR spectrum binning in
0.01 ppm increments, and with neighborhood parameter δ = 0.03 and 0.01, respectively. While the peak and multiplet descriptions of the 3-aminoisobutyrate
NMR spectrum may be essentially coherent, their resulting match sets do differ, with 22 features unique to either one of the match sets.
https://doi.org/10.1371/journal.pcbi.1005839.g001
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supplied spectral database. It then scores and ranks the compared metabolites, such that high
ranking metabolites are most likely to underlie the SNP-feature associations.
Spectral databases
The default spectral database used by metabomatching is acquired from the Human Metabo-
lome DataBase [24] (HMDB), which lists experimental proton NMR spectra for 835 metabo-
lites. In HMDB, the spectrum of a metabolite is described in two ways: as a list of peaks, and as
a list of multiplets (see Fig 1B). A peak is defined by a spectral position, expressed as a chemical
shift in parts per million (ppm), and a relative NMR intensity, that is the peak height expressed
relative to the highest peak in the spectrum. A multiplet is defined by a chemical shift range,
and a proton count. Peaks group into clusters, and for each such cluster in the peak descrip-
tion, there is, generally, a corresponding multiplet in the multiplet description whose range
encloses the cluster. Furthermore, the area under the curve delimiting the peaks of a cluster
can be related to the proton count of the corresponding multiplet [25]. The two descriptions
are usually, but not always, coherent.
Alternatively, metabomatching can use a database acquired from the Biological Magnetic
Resonance dataBank [26] (BMRB), which lists experimental proton NMR spectra for 670
metabolites. In BMRB, the spectrum of a metabolite is described only as a list of peaks.
Each metabolite, however, may have several peak description spectra, obtained in different
experiments.
Both HMDB and BMRB collect information on any metabolites found in the human
body. As a result, many of the spectra contained in the full spectral databases may be irrele-
vant for a specific mGWAS, typically because the corresponding metabolites may not be
contained in the studied biofluid. Metabomatching can therefore also use specific subsets of
the full spectral databases. For urine, the spectral database is derived from the urine metabo-
lome database (UMDB) [27] and contains proton NMR spectra for 180 metabolites, 124 if
based on BMRB. For serum, the spectral database is derived from the work of Gowda et al.
[12] and contains proton NMR spectra for 67 metabolites if based on HMDB, 49 if based on
BMRB.
Standard method
For the comparison of pseudospectra to reference spectra, we introduce a feature match set
Fδ(m) for every metabolite m in the reference database. Fδ(m) is defined to contain all features
f within a neighborhood of δ ppm of any spectrum peak listed in the peak description of m (see
Fig 1C). For the pseudospectrum of a given SNP r and the spectrum of every metabolite m, we
compute the match sum
X
f2FdðmÞ
b
2
rf
s2rf
; ð1Þ
with βrf the effect size and srf the standard error of the association between SNP r and feature f.
Even though the features are usually not independent, we consider the match sum to be χ2-dis-
tributed with |Fδ(m)| degrees of freedom, so as to define the score for the tested metabolite as
the negative logarithm of the corresponding p-value. As a result, while we use the scores to
rank metabolites for a given SNP, the scores do not inform on the statistical significance of a
spectrum-pseudospectrum match, nor do we compare scores obtained for the pseudospectra
of different SNPs.
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Settings
Because multiplet descriptions of the reference NMR spectra in HMDB can significantly differ
from peak descriptions, they can be considered as composing a separate spectral database. To
use this set, or its corresponding biofluid specific subsets, metabomatching can be run in mul-
tiplet mode, instead of the standard peak mode described above. The match set Fδ(m) used to
compute the match sum (1) for m is then defined to contain all features f falling in, or within δ
of, any multiplet range of metabolite m (see Fig 1C). Because multiplet ranges tend to pad their
corresponding peak cluster, the neighborhood parameter δ takes a smaller value in multiplet
mode than in peak mode. The resulting match sets are then comparable to their peak mode
counterparts, in general. However, differences between the two descriptions, in cluster posi-
tion, size, or even presence, occur for about 10% of metabolites in HMDB. These differences
can significantly affect metabomatching results.
Metabolome features that are common to the spectrum of a metabolite present in the study
samples correlate, and metabomatching can be set to take this correlation into account. The
correlation is strongest among neighboring features, which may be common to multiple
metabolites of spectra containing similar peak clusters, but also appears in features corre-
sponding to peaks in different spectrum clusters. Heuristically however, only the correlation
between neighboring features is detrimental to metabomatching, and decorrelation is there-
fore applied only to feature neighborhoods. Given the user-provided feature-feature correla-
tion matrix C^, match sum (1) is then modified to
X
f ;g2FdðmÞ
brf
srf
C  1
d;fg
brg
srg
; ð2Þ
where Cd;fg ¼
:
ð1   lÞC^fg Jd;fg þ lIfg provides decorrelation, with λ 2 [0, 1] the shrinkage param-
eter [28], which serves to regularize. Restriction to feature neighborhoods results from the
block diagonal matrix Jδ, with Jδ;fg = 1 if f and g are members of the same neighborhood, that is
if they are connected by a sequence of features in Fδ(m) each at most 2δ ppm apart, and I the
identity matrix.
Metabomatching includes two variants for cases where a SNP affects a pair of metabolites:
2-compound metabomatching if the effects are of equal directions, and ±-metabomatching if
the effects are of opposite directions. For 2-compound metabomatching, we compute the
match sum for pairs of metabolites by running the sum over pair match sets, defined as
Fδ(m1, m2)¼
: Fδ(m1) [ Fδ(m2). Metabolite pairs are accordingly scored and ranked. In ±-meta-
bomatching, standard (1-compound) metabomatching is run separately for each effect direction,
setting to 0 the effect size for associations in the other direction that exceed a user-provided p-
value threshold. 2-compound and ±-metabomatching can be combined into ±-2-compound
metabomatching for SNPs affecting at most one pair of metabolites in each direction.
By squaring β/s in match sum (1) or (2), χ2-scoring increases signal to noise ratio, both by
amplifying the contribution of strongly associated features to metabomatching scores, and by
ignoring effect directions. This increase applies indiscriminately, however, and may actually
favor competing metabolites more than the metabolite to identify. Therefore, for pseudospec-
tra where this increase is not necessary, such as those produced in mGWASes of high statistical
power, for example, stronger matches may be obtained with Z-scoring. Here, scores are com-
puted according to the match sum
X
f2FdðmÞ
brf
srf
ð3Þ
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which we consider to be normally distributed, under the null hypothesis, with zero mean and
variance |Fδ(m)|, even though the sampled features are not independent. To apply decorrela-
tion in Z-scoring metabomatching, match sum (3) is not modified, but the variance is com-
puted as |∑fg Cδ;fg|, with Cδ the block diagonal matrix as previously defined. As in χ2-scoring,
multiplet-mode and 2-compound variants applied by using the corresponding match sets in
match sum (3). Because Z-scoring is explicitly sensitive to effect directions, ±-metabomatching
is not required for SNPs affecting two metabolites with opposite effect directions. However,
the separate presentation of results of ±-metabomatching may be useful in cases where the
effect sizes are such as to cause metabolites matched with one effect direction to systematically
outrank metabolites matched with the other direction.
Output
To summarize, metabomatching is run for a given pseudospectrum: against a set of match sets,
defined by the selected spectral reference database, the mode, and neighborhood parameter δ;
where appropriate, as 1-compound, 2-compound, ±-, or ±-2-compound variant; and depend-
ing on performance, with or without decorrelation, and with χ2- or Z-scoring. Metabomatching
outputs the score for each metabolite in the spectral database, and produces a figure showing
the pseudospectrum and the spectra of the highest ranked candidate metabolites (Fig 2).
Simulation
We bin the chemical shift range [0, 10] uniformly, in 0.01 ppm increments, and round refer-
ence spectra to the binning. We express the spectrum of each metabolite as a vector hm, with
Fig 2. Metabomatching results figure. The metabomatching results figure, shown here for the same AGXT2 pseudospectrum as in Fig 1.
The figure shows the metabomatching settings used, the pseudospectrum with features color-coded by effect size, and, for the eight highest
ranked candidate metabolites, the score, name, and reference NMR spectrum with match sets color-coded according to the height of the
NMR spectrum peak they derive from.
https://doi.org/10.1371/journal.pcbi.1005839.g002
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hmj the height of the peak in bin j, set to 0 if the spectrum does not include bin j, and define
the size of the spectrum as sm¼:
P
j h
m
j . To model the genetic association between a SNP and
metabolite m, we randomly assign a genotype gi 2 {0, 1, 2} to each individual (i 2 [1, 400]),
according to a minor allele frequency of 0.2, and build the feature metabolome M0 of elements
M0ij ¼
:
bhmj gi þN ð0; 1Þ: ð4Þ
Because the number of individuals, the minor allele frequency and the amplitude of noise are
fixed, the strength of the association is controlled fully by the choice of effect size β. We then
associate the metabolome M0 with the genotype g, and apply metabomatching to the resulting
pseudospectrum. For each metabolite, we repeat this procedure 1 000 times, and compute rm
90
,
the 90th percentile over the 1 000 ranks of m. We consider metabomatching successful for m if
rm
90
¼ 1.
From the results of this simple model, shown in Fig 3A for UMDB, we can make two
important observations. First, that if the effect size is large enough, metabomatching can iden-
tify any metabolite. Second, that the performance of metabomatching, characterized here by
rm
90
, is strongly correlated with the spectrum size.
Fig 3. Metabomatching results on simulated metabolomes. A. Metabomatching performance, measured as rm
90
, the 90th percentile of 1 000 ranks
obtained for m by metabomatching pseudospectra build from the association with M0, for β = 0.2 (filled dots) and β = 1.6 (empty dots), as a function of the
size of the metabolite spectrum.For β = 0.2, the correlation between rm
90
and sm is −0.71, with p * 10−26. B. As in (A), but for metabolome Mα, with β = 1.6,
Na = 64 and α = 0.6. C. For UMDB and δ = 0.02, number of match sets (η) that contain each feature (uniform binning in 0.01 ppm increments). D.
Metabomatching performance, measured as rm
90
, for Mα, with β = 1.6, Na = 64 and α = 0.6, as a function of η of the leading peak of the metabolite spectrum,
that is the peak with hj = 1. Metabolite sizes are rounded. For sm = 1, 2, and 3, respectively, correlations ρ are 0.86, 0.79, and 0.76, with p-values *10−10,
10−4, and 10−4.
https://doi.org/10.1371/journal.pcbi.1005839.g003
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We then add genetic noise to the model, in the form of Na randomly drawn features that
also associate, with a randomly drawn direction, with genotype g. We insert these genetic
noise features in the model by adding the terms aj 2 {−1, 0, 1}, such that ∑j |aj| = Na, when
building the feature metabolome Mα of elements
Maij ¼
:
bhmj gi þ abgiaj þN ð0; 1Þ;
where α< 1. As the amount Na, or amplitude α, of genetic noise increases, metabolite m faces
wider, respectively stronger, competition from other metabolites in the spectral database.
When β is small, random noise still determines metabomatching performance, and rm
90
is
similar to that for metabolome M0 shown in Fig 3A. When β is large, however, genetic noise
dominates. As shown in Fig 3B (and S4 Fig for other settings and for both UMDB and
HMDB), metabomatching can then no longer identify all metabolites consistently, because
other metabolites in the database outscore m by matching genetic noise features. Some of these
other metabolites may obtain their score from genetic noise features only, but true competition
for m is provided by metabolites that match both genetic noise features and features of m.
Because these competing metabolites have spectra similar to the spectrum of m, they tend to
be viable metabomatching candidates. For metabolites with a single peak f, we can count the
number of metabolites of match set that contain f to determine the size of this competing
group. In Fig 3C, we show this number, η(f) for UMDB, and in Fig 3D we see that rm
90
for
metabolites of size 1 correlates strongly with η. For larger spectra, where we take η for the lead
feature (the one of height 1), the correlation holds, but η is less representative of the size of the
competing group.
Results
We first tested metabomatching on pseudospectra obtained in the urine NMR mGWAS [17]
in the CoLaus study [29]. NMR data were aligned, normalized, and uniformly binned in
0.005 ppm increments. The resulting untargeted metabolome contained 1,276 features for 835
individuals. As references, we used SNP-metabolite associations that were previously reported
in targeted mGWASes on urine NMR [8, 18, 20] with a p-value below 10−5 and involving a
metabolite for which an NMR spectrum is listed in UMDB. If a CoLaus SNP located within
500kb of the reference SNP associated with p< 10−6 with at least one feature contained in the
match set of the reference metabolite (with δ = 0.03 in peak mode, 0.01 in multiplet mode), we
considered the CoLaus SNP pseudospectrum testable, and assumed the reference metabolite to
be the metabolite underlying the SNP-feature association. This resulted in nine testable pseu-
dospectra, each with a single reference metabolite.
Metabomatching with default settings (peak mode, χ2-scoring, and without decorrelation),
and using the urine specific UMDB reference database, was successful for eight of the nine
testable pseudospectra, ranking the reference metabolite first three times and in the top ten
five times (column PXC of Table 1, detailed results in S1 Fig). For the SOSTDC1 SNP, the pseu-
dospectrum (S1C Fig) shows strong inflation across almost the entire chemical shift range,
making metabomatching fail systematically. Metabomatching in multiplet mode performed
better overall (column MXC), ranking the reference metabolites first six times and second twice,
though the performance was qualitatively different only for the HPD SNP pseudospectrum,
for which the testable association involved a different reference metabolite (S1F and S1G Fig).
Decorrelation had little effect on rankings, in either mode, provided a shrinkage parameter λ
greater than 0.1 was used (results for λ = 0.5 in Table 1 columns PXD and M
X
D, other values of λ
in S1 Table).
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Z-scoring metabomatching properly ranked the reference metabolites for the pseudospectra
characterized by the strongest associations, that is those for SNPs in AGXT2, PYROXD2, and
SLC7A9. Pseudospectra with weaker associations fared worse, with Z-scoring metabomatching
ranks significantly lower than their χ2-scoring counterparts, except for the UPS9 pseudospec-
trum. For the SLC6A20 and SLC6A13 pseudospectra, the reference metabolite is outranked by
a number of metabolites of spectra that obtain their score by matching a group of strongly cor-
related features. Applying decorrelation reduces this correlation-based score, thereby signifi-
cantly improving the rank of the reference metabolite in both peak- and multiplet-mode (see
S3 Fig).
Using the full HMDB spectral database (S2 Table), metabomatching ranked the reference
metabolites for PYROXD2, PNMT, HPD markedly lower, due to stronger competition among
the larger pool of candidate metabolites. Using the UMRB or BMRB spectral databases (S2
Table), metabomatching ranks the reference metabolite for PNMT lower, for PYROXD2
higher, but is otherwise comparable to UMDB or HMDB, respectively.
We then tested metabomatching on pseudospectra obtained in the urine mGWAS [20] in
the SHIP study [30]. NMR data were normalized, binned in 0.0005 ppm increments, then pro-
cessed with FOCUS [31]. The resulting untargeted metabolome contained 166 features for
3,861 individuals. In addition, NMR data were manually annotated using Chenomx NMR
Suite 7.0. The resulting targeted metabolome contained the concentrations of 59 metabolites
for the same 3,861 individuals. Having both metabolome features and metabolite concentra-
tions in the same sample allowed for the direct comparison of SNP-metabolite association
results via metabomatching with targeted metabolite quantification followed by association.
We considered the pseudospectrum of a SNP associating with p< 10−6 with both a metabolite
and at least one feature contained in the metabolite spectrum testable. This resulted in nine-
teen testable SNP-metabolite associations involving fourteen SNPs.
Because testing is in the same samples, and because of the higher sample size of the study,
metabomatching results for SHIP pseudospectra are more nuanced than they were for CoLaus
pseudospectra. For the nine SNPs that associate with a single metabolite, metabomatching in
default settings ranked the reference metabolite first five times, and in the top ten four times
Table 1. CoLaus metabomatching results. Ranks of reference metabolites obtained for CoLaus pseudospectra, with UMDB as the spectral reference data-
base, and with: peak- (P) or multiplet-mode (M), χ2- (X) or Z-scoring (Z), and without (C) or with decorrelation (D). Neighborhood parameter is δ = 0.03 in
peak-mode, 0.01 in multiplet-mode. Shrinkage parameter is λ = 0.5 for decorrelation, 1 without. Reference metabolites are obtained from testable associations
collected from targeted mGWAS [8, 18, 19]. Squares (□) indicate ranks not in the top 10% of UMDB listed metabolites, that is ranks greater than 18. Individual
metabomatching figures including the eight highest ranked metabolite candidates for each pseudospectrum can be found in S1 Fig. Due to the differences in
the peak and multiplet descriptions, the association of the HPD SNP with α-hydroxyisobutyrate is testable only in peak mode (S1F Fig), the association with
3-hydroxyisovalerate only in multiplet mode (S1G Fig).
Locus Reference Association Feature Association Ranks
Gene Chr SNP Metabolite p SNP Feat. p PXC P
X
D M
X
C M
X
D P
Z
C P
Z
D M
Z
C M
Z
D
SLC6A20 3 rs17279437 dimethylglycine 1.1 × 10−46 rs4327428 2.933 7.3 × 10−10 2 1 2 1 □ 7 12 1
AGXT2 5 rs37369 3-aminoisobutyrate 2.4 × 10−252 rs37369 1.203 3.9 × 10−42 1 1 1 1 2 1 1 1
SOSTDC1 7 rs10238442 taurine 4.0 × 10−6 rs17169536 3.393 7.6 × 10−7 □ □ □ 12 □ □ □ □
PYROXD2 10 rs4539242 trimethylamine 2.8 × 10−23 rs4488133 2.857 1.3 × 10−98 5 4 2 2 4 1 4 3
SLC6A13 12 rs11613331 3-aminoisobutyrate 2.5 × 10−15 rs10774021 1.193 9.5 × 10−10 4 4 1 1 14 5 □ □
HPD 12 rs4760099 α-hydroxyisobutyrate 2.2 × 10−80 rs7314056 1.363 9.8 × 10−11 3 1 □ □
3-hydroxyisovalerate 2.4 × 10−7 2 5 □ □
PNMT 17 rs8069451 tyrosine 7.9 × 10−22 rs676882 6.897 1.8 × 10−8 3 3 1 1 □ □ □ □
SLC7A9 19 rs8101881 lysine 3.3 × 10−25 rs6510300 1.733 3.9 × 10−15 1 1 1 1 1 2 1 2
UPS9 19 rs13343495 sucrose 3.4 × 10−6 rs17273533 5.417 4.0 × 10−7 1 2 1 1 2 2 3 1
https://doi.org/10.1371/journal.pcbi.1005839.t001
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(see Table 2 column PXC, detailed results in S2 Fig). For the CPS1 and HPD SNPs, which associ-
ate with two metabolites each, metabomatching ranked one metabolite first, the second in the
top ten, and 2-compound metabomatching ranked the reference metabolite pair first. The
pseudospectra for the three remaining SNPs are more complex. While the NAT2 SNP only
associates with formate, its pseudospectrum (S2N Fig) indicates the presence of additional
associations, in both effect directions. We therefore applied ±-2-compound metabomatching
(S2O Fig), which ranks a metabolite pair that includes formate first, in the β> 0 direction.
With associations with three reference metabolites, the PNMT SNP pseudosepctrum (S2U Fig)
is too complex for metabomatching, or 2-compound metabomatching, to provide any of the
reference metabolites as plausible candidates. The SLC6A19 SNP pseudospectrum (S2J Fig) is
similar to the PNMT SNP pseudospectrum, but with weaker associations. Because the second-
ary associations are closer to the noise background, metabomatching still provides top ten
ranks for the two reference metabolites. 2-compound metabomatching, however, does not
properly rank the reference pair.
Metabomatching in multiplet mode shows similar results for most SNPs (column MXC).
However, for the CPS1, XYLB, HPD SNPs, the multiplet ranges describing the spectra of the
respective reference metabolites are wide (between 0.16 and 0.28 ppm) even though each
range encloses only a single peak. The resulting multiplet-mode neighborhoods have a higher
number of degrees of freedom than their peak-mode counterparts, yet produce similar sum
values. This lowers the scores of the reference metabolites, which are then outranked by
Table 2. SHIP metabomatching results. Metabomatching ranks of reference metabolites obtained for SHIP pseudospectra, with UMDB as the spectral ref-
erence database, and with: peak- (P) or multiplet-mode (M), χ2- (X) or Z-scoring (Z), and without (C) or with decorrelation (D). Neighborhood parameter is δ =
0.03 in peak-mode and 0.01 in multiplet-mode. Shrinkage parameter is λ = 0.5 for decorrelation, 1 without. Ranks obtained with 2-compound metabomatching
are shown in bold, those obtained with ±-2-compound metabomatching in bold and italic. Squares (□) indicate ranks not in the top 10% of UMDB listed metab-
olites, that is ranks greater than 18. Individual metabomatching figures including the eight highest ranked metabolite candidates for each pseudospectrum can
be found in S2 Fig.
Locus Reference Association Feature Association Ranks
Gene Chr SNP Metabolite p Feature p PXC PXD PZC PZD MXC MXD MZC MZD
DAB1 1 rs558475 hippurate 3.9 × 10−7 3.949 3.6 × 10−8 1 1 1 1 1 1 1 1
CPS1 2 rs2216405 glycine 2.9 × 10−11 3.555 4.9 × 10−9 1 1 □ □ 3 1 □ □
creatine 7.5 × 10−11 1 1 □ □ 16 11 □ □
XYLB 3 rs2070486 glycolate 1.4 × 10−9 3.937 2.4 × 10−9 2 1 5 2 16 16 □ □
SLC6A20 3 rs17279437 dimethylglycine 1.1 × 10−46 2.916 1.1 × 10−21 1 2 2 2 1 1 1 1
ENTPPL 4 rs7654111 ethanolamine 2.3 × 10−26 3.126 5.0 × 10−16 1 1 4 5 1 1 2 2
SLC6A19 5 rs7719875 histidine 2.4 × 10−14 6.877 6.4 × 10−12 8 8 10 11 10 8 8 8
tyrosine 6.5 × 10−10 9 13 12 12 12 14 □ 14
AGXT2 5 rs37369 3-aminoisobutyrate 2.4 × 10−252 1.171 3.7 × 10−252 1 1 2 2 1 1 1 1
DMGDH 5 rs248386 dimethylglycine 1.0 × 10−13 2.916 1.8 × 10−8 5 5 □ □ 2 1 □ □
SLC36A2 5 rs3846710 glycine 1.1 × 10−10 3.555 6.3 × 10−9 1 1 2 2 1 1 2 5
NAT2 8 rs1495743 formate 9.5 × 10−60 3.189 1.6 × 10−104 1 1 1 1 1 1 1 1
SLC6A13 12 rs11613331 3-aminoisobutyrate 2.5 × 10−15 1.190 5.0 × 10−16 5 5 3 3 4 4 3 3
HPD 12 rs4760099 α-hydroxyisobutyrate 2.2 × 10−80 1.345 2.2 × 10−64 1 1 1 1 2 1 1 1
3-hydroxyisovalerate 2.4 × 10−7 1 1 1 1 3 4 2 5
PNMT 17 rs8069451 tyrosine 7.9 × 10−22 6.877 4.4 × 10−17 □ □ □ □ □ □ □ □
histidine 7.3 × 10−21 □ □ □ □ □ □ □ □
alanine 2.3 × 10−11 18 18 16 □ 17 □ 15 □
SCL7A9 19 rs8112297 lysine 5.0 × 10−16 3.003 9.4 × 10−7 9 9 15 17 15 11 17 □
https://doi.org/10.1371/journal.pcbi.1005839.t002
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competing metabolites, particularly in 2-compound metabomatching (S2D, S2E, S2G, S2S and
S2T Fig).
Z-scoring metabomatching underperforms χ2-scoring overall (columns PZC and M
Z
C), yet
Z-scoring ranks obtained for the reference metabolites are close to their corresponding χ2-
scoring ranks for all but two pseudospectra. For the CPS1 and DMGDH pseudospectra, the
association of the lead feature is too weak to compensate for the associations of opposite effect
direction of other features captured by the match sets of the corresponding reference metabo-
lites (see S2B and S2L Fig). The resulting penalties incurred under Z-scoring produce low ref-
erence metabolite ranks.
FOCUS combines neighboring features into a single representative feature, obtained either
by peak picking or by integration of the NMR curve in the neighborhood. As a result, the effect
on metabomatching ranks of correlation in feature neighborhoods is weaker because neigh-
borhoods contain fewer features after FOCUS processing. Correspondingly, ranks with dec-
orrelation are essentially equal to ranks without decorrelation (columns PXD, P
Z
D,M
X
D, and M
Z
D).
Using the full HMDB spectral database (S3 Table), metabomatching ranked the reference
metabolites for SLC6A20, SLC7A9 markedly lower. Using the UMRB or BMRB spectral data-
bases (S3 Table), metabomatching ranks the reference metabolites for SLC6A19, SLC6A13, and
PNMT higher, but is otherwise comparable to UMDB or HMDB, respectively.
Discussion
Under the test conditions used here, metabomatching has shown to be remarkably successful
in identifying the metabolites underlying the feature associations in the investigated pseudos-
pectra, by generally highly ranking the respective reference metabolites. In normal conditions,
where the underlying metabolites are not known, the performance of metabomatching
depends on the characteristics of the untargeted mGWAS.
First and foremost, metabomatching can only identify an underlying metabolite for which
a spectrum is listed in the supplied spectral database. Here, we only tested metabomatching on
untargeted associations that we could link to reference metabolites with listed spectra. How-
ever, both the CoLaus [17] and SHIP [20] mGWASes discovered feature associations to which
metabomatching did not assign plausible candidates, likely because the spectra of the underly-
ing metabolites are absent from HMDB.
Similarly, metabomatching can only properly rank the metabolite to identify if the NMR
spectrum in the provided database does not significantly deviate from the NMR spectrum as
measured in the experimental conditions specific to the mGWAS. Such deviations are com-
mon, and can be significant. For example, if we compare match sets pairs for the 318 metabo-
lites of spectra that are listed both in HMDB and BMRB, but were not necessarily acquired
under identical experimental conditions, we find that the match sets of 133 metabolites differ
by at least one feature and that the match sets of 29 metabolites have no common features.
Increasing the neighborhood parameter δ in the match set definitions can mitigate such
deviations, but in turn, larger neighborhoods make metabolites generally more difficult to
distinguish.
If the metabolite underlying an observed metabolome feature association is listed in the
database, and if the listed spectrum does not significantly deviate from the mGWAS specific
spectrum, then the underlying metabolite obtains a high metabomatching score. For the
metabolite to also obtain a high rank, however, it needs to outscore other listed metabolites.
If the observed feature association is strong enough, the underlying metabolite outscores all
those metabolites whose spectra do not include the associated feature, and whose scores there-
fore rely essentially on the level of noise in the pseudospectrum. The p-value threshold of
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5 × 10−8, the Bonferroni threshold for significance when correcting only for the number of
tested SNPs, is usually sufficient for signal-based scores to outrank almost all noise-based
scores.
The main competition for top metabomatching rank then stems from metabolites with a
listed spectrum which also matches the associated feature. Therefore, the more distinctive the
underlying metabolite, that is the more dissimilar it is from the other metabolites in the spec-
tral database, the higher it ranks. The distinctiveness of a metabolite is not an intrinsic prop-
erty of the metabolite spectrum, not only because it depends on the chosen database, but
because it depends on the mGWAS itself. For example, small peaks that contribute to the dis-
tinctiveness of a spectrum may be lost in a low powered mGWAS, thereby making metabolites
distinct in spectra indistinguishable for metabomatching. However, the strongest matches
among our test cases, that is those for loci AGXT2 and SLC7A9 in CoLaus (Table 1), and
DAB1, ENTTPL, and AGXT2 in SHIP (Table 2), follow a trend, similar to that suggested by
our simulation results: the greater the number of clusters of peaks in the spectrum of a metabo-
lite, the greater, and more resilient, its rank. Even though not all spectrum peaks will necessar-
ily show strong association, metabolites with high cluster count spectra do tend to produce
high cluster count pseudospectra. The corresponding matches are generally characterized in
both high score and high distinctiveness.
The ideal settings under which to run metabomatching are specific to every mGWAS, and
depend on the experimental conditions under which the feature metabolome was acquired,
the data processing applied, and the statistical power of the study. Consequently, while the
default settings (1-compound, HMDB, peak-mode, χ2-scoring, δ = 0.03 and without decorrela-
tion) provide a good starting point, the performance of metabomatching can be significantly
improved by adapting the settings to the study.
The greatest impact on performance is likely achieved simply by selecting the appropriate
biofluid-specific, and therefore smaller, spectral database. Then, it is advisable to run metabo-
matching with wide neighborhoods (δ = 0.05) first, to uncover potential issues of deviations
of study spectra from reference spectra. While wide neighborhoods tend to muddle metabo-
matching results in general, good matches should still be obtained in specific cases where
the SNP associates with multiple peaks in distinct clusters of a metabolite spectrum or with
peaks of a distinctive metabolite spectrum. Guided by the performance on such cases, metabo-
matching should be run with progressively smaller values of δ, until the smallest δ, which still
accounts for the observed deviations between study and reference spectra, is reached.
Pseudospectra should then be individually inspected for the need for multiple-compound
metabomatching: 2-compound metabomatching if the associations are of the same effect
direction, but no single metabolite matches them all; ±-metabomatching if the associations are
of opposite effect directions.
With biofluid, δ and metabomatching variants defined, runs with decorrelation (taking λ =
0.5) or Z-scoring can be tested. Which scoring or decorrelation setting performs better is diffi-
cult to evaluate, and may be essentially subjective unless prior knowledge about the underlying
metabolites is available.
Finally, metabomatching against other reference biofluid-specific subsets, such as those of
BMRB or of multiplet description HMDB, may prove to provide stronger matches due to bet-
ter conforming reference spectra, while metabomatching against full HMDB or BMRB may,
for unmatched pseudospectra, identify metabolites that occur in the studied biofluid, while not
being annotated as such.
Applying this procedure allows metabomatching to run in the settings best suited to the
investigated mGWAS, and present the most likely candidate metabolites, among the provided
set of reference metabolites, underlying observed SNP-feature associations. Because the
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spectral database never fully conforms to the set of metabolites investigated in any specific
study, however, metabomatching cannot provide definitive identification. In some cases,
additional evidence can strengthen metabomatching candidates, such as a direct biological
connection between gene and candidate metabolite (ENTTPL,DMGDH) or coherent targeted
mGWAS association results (all testable associations presented here, but CPS1, AGXT2,
SLC6A13, and HPD, in particular, for which targeted association results also exist in blood and
mass spectrometry mGWASes [7]). For the remaining cases, in-sample identification through
manual annotation or further measurement from spiking experiments or 2-dimensional NMR
spectroscopy may be required to verify the candidates provided by metabomatching.
Conclusion
While not yet as widespread as the targeted approach, the untargeted approach to metabo-
lome-wide genome-wide association studies has already shown compelling results. Because it
analyses all measured metabolome features, the untargeted approach more fully exploits exper-
imental data and may discover genetically determined metabolites that were missed, because
they eluded identification, by a targeted approach. By focusing the identification effort on the
comparatively few metabolites found to be genetically determined, the untargeted approach
also presents the pragmatic advantage of shortening the path from spectral metabolome data
to mGWAS results.
Metabomatching further reduces this identification effort, by combining genetic spiking
information with spectral reference data to assign candidate metabolites to genetically associ-
ated metabolome features. In addition, because identification through genetic spiking is not
an in-sample procedure, metabomatching becomes of particular interest when applied in an
mGWAS that combines untargeted and targeted approaches. In such a combined mGWAS,
metabomatching can both provide an independent line of evidence for in-sample identifica-
tions of metabolites, and inform on the identity of metabolites that were missed by the targeted
approach because they eluded in-sample identification.
Naturally, while focus was placed here, and in previous applications of metabomatching,
on pseudospectra resulting from genetic association with NMR features, metabomatching is
not limited to genome-wide association studies. Any trait that influences, or is influenced by,
metabolome features produces an association pseudospectrum to which metabomatching can
assign candidates. Notably, metabolome-wide association studies, analyzing the effects of the
metabolome on organismal traits, would similarly benefit from both the untargeted approach
and metabomatching.
The performance of metabomatching is inherently linked to the strength of genetic spiking
and the quality of spectral databases. With increasing mGWAS sample sizes, and the continu-
ing efforts to establish spectral databases that are more complete and better annotated, both
conditions are expected to improve. Metabomatching is therefore not only likely to become a
valuable tool for exploring the links to metabolites of listed spectrum, but may also provide
impetus to complete databases of spectral information for human metabolites, reducing
instances where no good match can be found.
Software
Metabomatching is written for Matlab and compatible with octave. Documentation and code
can be obtained from the metabomatching website http://www.unil.ch/cbg/index.php?title=
metabomatching or GitHub. Metabomatching is also available as a docker container, and
within the metabolomics e-infrastructure PhenoMeNal http://phenomenal-h2020.eu.
Metabomatching: Using genetic association to identify metabolites in 1H NMR spectroscopy
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1005839 December 1, 2017 13 / 17
Supporting information
S1 Table. CoLaus metabomatching results for different values of the shrinkage parameter
λ. Decorrelation has only a minor effect on metabomatching rankings. For λ 2 [0.1, 0.9] only
the HPD-α-hydroxyisobutyrate rank is significantly affected, going to 1 from 4 (at λ = 1).
Without any shrinkage (λ = 0), however, several metabolites acquire artificially high scores,
leading to lower ranks of the control metabolites for SLC6A20 and UPS9 in both peak- and
multiplet-mode.
(PDF)
S2 Table. CoLaus metabomatching results against HMDB, UMRB, and BMRB spectral
databases. Metabomatching performance using the spectral reference database UMRB, that is
the urine-specific subset of BMRB, is similar to the performance using the spectral reference
database UMDB. Trimethylamine ranks higher for PYROXD2, because the competing metabo-
lites score lower in UMRB than UMDB. Tyrosine ranks lower because the BMRB listed spec-
trum deviates more from its pseudospectrum-implied CoLaus spectrum than the HMDB
spectrum does. α-hydroxyisobutyrate and 3-hydroxyisovalerate do not have spectra listed in
BMRB. Using the full HMDB or BMRB databases introduces more competing metabolites, sig-
nificantly affecting the ranks of PYROXD2 and PNMT.
(PDF)
S3 Table. SHIP metabomatching results against HMDB, UMRB, and BMRB spectral data-
bases. We see that the spectra listed in BMRB tend to correspond better, overall, to the pseu-
dospectrum-implied spectra of the metabolites in SHIP, resulting in better metabomatching
ranks. This applies in particular to histidine, tyrosine, and 3-aminoisobutyrate, resulting in sig-
nificantly better ranks for SLC6A19, SLC6A13, and PNMT. Strong matches in DAB1, SLC6A20,
ENTPPL, AGXT2, SLC36A2, and NAT2 maintain their high ranks when metabomatching
is run against the full databases HMDB and BMRB. The ranks of weaker matches, which
already suffered strong competition when using the urine-specific subsets, drop; in cases such
as SLC6A20 and SLC7A9, significantly so.
(PDF)
S1 Fig. CoLaus metabomatching figures. Full results for UMDB peak-mode χ2-scoring
metabomatching for each of the nine testable CoLaus pseudospectra. Multiplet-mode
metabomatching results are shown only for HPD, where they differ notably from peak-
mode metabomatching results. The navigation table in the footer allows direct access to a
specific pseudospectrum. The reference metabolite is indicated by a hash mark (#) next to
its name.
(PDF)
S2 Fig. SHIP metabomatching figures. Full results for UMDB peak-mode χ2-scoring metabo-
matching for each of the fourteen testable SHIP pseudospectra. 2-compound metabomatching
results are shown for CPS1 and HPD, and ±-metabomatching results for NAT2. Multiplet-
mode metabomatching results are shown only where they differ notably from peak-mode
metabomatching results, that is for CPS1, XYLB, and HPD. The navigation table in the footer
allows direct access to a specific pseudospectrum. The table is repeated on subsequent pages.
The reference metabolites are marked with a hash mark (#) next to their name. To maintain
a consistent layout where necessary, long metabolite names are replaced by the metabolite
chemical abstract service registry number (CASRN), and a conversion table added to the bot-
tom of the figure.
(PDF)
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S3 Fig. An example of the effect of decorrelation in metabomatching. The pseudospectrum
of rs10774021 in SLC6A13 is characterized by a single significantly associated feature: feature
1.19. (A) With χ2-scoring metabomatching, the association with feature 1.19 is sufficient for
metabolites of spectrum matching feature 1.19, including the reference metabolite 3-aminoiso-
butyrate, to obtain top ranks. (B) With Z-scoring metabomatching, metabolites of spectrum
matching 1.19 are outranked by metabolites matching peaks in the region between 3.6 and
3.9 ppm, which produces, on its own, a score of 11.8. (C) The 3.6 to 3.9 ppm region is charac-
terized by strong correlation. By applying decorrelation, with λ = 0.5, the score produced by
the region, on its own, is reduced to 0.8. Correspondingly, with decorrelation, 3-aminoisobu-
tyrate outranks most metabolites that, without decorrelation, ranked highly by matching the
3.6 to 3.9 ppm region.
(PDF)
S4 Fig. Simulation results for metabolome model including genetic noise. Median rm
90
, with
metabolites grouped by their rounded size, and from light to dark blue, β = 0.2, 0.4, 1.6. We
show results for UMDB and HMDB, neighborhood parameters δ = 0.02 and 0.05, χ2- and Z-
scoring, and two genetic noise levels, defined by Na and α set to 16 and 0.4, and 64 and 0.6,
respectively. From these cases, we see that the performance of metabomatching is consistently
stronger in the smaller spectral database UMDB, and for smaller δ. For the weaker genetic
noise, the median rm
90
is equal to, or close to, 1, for sufficiently large β, except in the case of δ =
0.05 in HMDB for sm = 2. For strong genetic noise, metabomatching performance is consis-
tently poorer, with rm
90
often far from 1. χ2-scoring performs better than Z-scoring under weak
genetic noise. When genetic noise is strong, however, Z-scoring performs almost invariably
better: when β is large, there are sizes sm for which Z-scoring produces rm
90
close to 1 while χ2-
scoring fails to do so.
(PDF)
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